CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
questionnaire administration +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00952848
NCT00952848Phase 2Completed

The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial

Virginia Commonwealth University·interventional·Posted Aug 6, 2009·Updated Mar 29, 2017

In Brief

A Phase 2 clinical trial evaluating questionnaire administration, Sensory Neuropathy Scale instrument, and 2 other interventions for Chemotherapeutic Agent Toxicity and 4 related conditions. Completed, enrolled 18 participants.

Detailed Summary

RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer. PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2009
Enrollment StartJun 12, 2009
Primary CompletionOct 1, 2009
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.9 years ago

Interventions

questionnaire administrationother

Pain Rating Score

Sensory Neuropathy Scale instrumentother

ECOG Common Toxicity Criteria for Sensory Neuropathy scale

Quality of Life instrumentother

Uniscale 0-100 scale global quality of life

MC5-A Scrambler devicedevice

Electrical stimulation for 60 minutes